Stockscreener 앱 받기
1.27
7.63%
0.09
전일 마감가:
$1.18
열려 있는:
$1.205
하루 거래량:
2.12M
Relative Volume:
2.31
시가총액:
$114.40M
수익:
-
순이익/손실:
$-93.61M
주가수익비율:
-0.6019
EPS:
-2.11
순현금흐름:
$-71.16M
1주 성능:
+27.00%
1개월 성능:
+33.68%
6개월 성능:
-22.09%
1년 성능:
-0.78%
1일 변동 폭
$1.2015
$1.39
1주일 범위
$1.03
$1.39
52주 변동 폭
$0.9204
$2.11
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
IMUX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.27 | 114.40M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-25 | 개시 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-27 | 개시 | B. Riley Securities | Buy |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2021-04-15 | 개시 | Aegis Capital | Buy |
| 2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-07 | 재개 | ROTH Capital | Buy |
| 2020-07-20 | 개시 | BMO Capital Markets | Outperform |
| 2020-06-05 | 개시 | Wedbush | Outperform |
| 2020-05-11 | 개시 | H.C. Wainwright | Buy |
| 2020-03-25 | 개시 | ROTH Capital | Buy |
| 2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
Immunic drug candidate may offer new obesity treatmentICYMI - Proactive financial news
H.C. Wainwright maintains Immunic stock Buy rating, $10 target - Investing.com
Market movers: Walmart, Palantir, Immunic, Alibaba… - Proactive Investors UK
Immunic highlights IMU-856’s potential as weight management therapy - Proactive Investors UK
Immunic's IMU-856 shows promise in weight management - Investing.com
Immunic’s IMU-856 shows promise for obesity treatment - Proactive Investors USA
Immunic announces IMU-856 demonstrated dose-dependent increase - TipRanks
Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase Of Glp-1 -February 20, 2025 at 07:31 am EST - Marketscreener.com
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing - PR Newswire
Immunic (IMUX) to Release Quarterly Earnings on Thursday - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat
Pleasing Signs As A Number Of Insiders Buy Immunic Stock - Simply Wall St
Immunic Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Immunic (NASDAQ:IMUX) Downgraded to Sell Rating by StockNews.com - MarketBeat
IMUX stock touches 52-week low at $0.92 amid market challenges - MSN
Breaking Barriers: Immunic CSO marks International Day of Women and Girls in Science - Proactive Investors UK
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Immunic CEO on key MS trial data coming in April - Proactive Investors USA
Immunic Inc (IMUX) Becoming More Attractive for Investors - Knox Daily
Immunic Inc’s results are impressive - US Post News
Market Recap: Immunic Inc (IMUX)’s Negative Momentum, Closing at 0.95 - The Dwinnex
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in January - MarketBeat
Immunic announces attendance at February investor and scientific conferences - Proactive Investors USA
Immunic to Participate in Investor and Scientific Conferences in February - PR Newswire
EQS-News: Immunic to Participate in Investor and Scientific Conferences in February - sharewise
Immunic (NASDAQ:IMUX) Upgraded by StockNews.com to "Hold" Rating - MarketBeat
Short Interest in Immunic, Inc. (NASDAQ:IMUX) Increases By 14.9% - Defense World
StockNews.com Upgrades Immunic (NASDAQ:IMUX) to “Hold” - Defense World
Vanguard Group Inc. Reduces Stake in Immunic Inc. - GuruFocus.com
HB Wealth Management LLC Acquires New Shares in Immunic, Inc. (NASDAQ:IMUX) - Defense World
IMUX Stock Touches 52-Week Low at $0.97 Amid Market Challenges - MSN
Immunic, Inc. (NASDAQ:IMUX) Sees Large Increase in Short Interest - MarketBeat
Jane Street Group LLC Grows Position in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $12.67 - Defense World
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Brokerages - MarketBeat
Immunic eyes transformative year ahead for MS therapy vidofludimus calciumICYMI - Proactive Investors Australia
Immunic ‘on track’ with MS clinical trials testing vidofludimus calcium - Multiple Sclerosis News Today
Immunic (NASDAQ:IMUX) Earns “Buy” Rating from D. Boral Capital - Defense World
Immunic COO Jason Tardio discusses key 2024 highlights, 2025 milestones - Proactive Investors Australia
Immunic eyes key data readout from multiple sclerosis trial in 2025 - Proactive Investors Australia
D. Boral Capital Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):